Hormonal
Subcutaneous semaglutide (0.5-1.0 mg) and oral semaglutide (7-14 mg) significantly improve glycemic control (HbA1c reduction) in patients with type 2 diabetes compared to placebo and various active control drugs.
For individuals with type 2 diabetes, semaglutide (available as a once-weekly injection or daily oral tablet) is highly effective at lowering blood sugar levels (HbA1c) compared to many other treatments, including insulin and other common diabetes medications. It offers a significant advantage in achieving target HbA1c levels (<7%) for a large proportion of patients. The risk of hypoglycemia is relatively low, and the once-weekly dosing can help improve compliance.
The results after 30–56 weeks show that semaglutide performs significantly better in reducing HbA1c than other controls, including placebo, insulin glargine, canagliflozin, dulaglutide, sitagliptin, liraglutide, and exenatide extended release.
Why this rating
Based on multiple phase-3 clinical trials (SUSTAIN 1-5, 7-10, PIONEER series) involving thousands of patients.
Source
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Yalin Liu et al. · Frontiers of Medicine · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →